70 terminated. 70 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 70 | Terminated 70 |
| Phase 2 | 7 | Terminated 7 |
Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only 177Lu-DOTA-rosopatamb, Standard of Care - Metastatic Prostate Cancer | Phase 3 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 16 | 2023-08-29 | 2026-02-20 |
| Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy Oxycodone, Acetaminophen, Ketamine - Pain Management, Opioid Use | Phase 2 / Phase 3 | Terminated | Wake Forest University Health Sciences | 58 | 2023-04-18 | 2026-06-15 |
| Ga-68-PSMA-11 in Men With Prostate Cancer Ga-68-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Terminated | Timothy Hoffman | 38 | 2021-07-27 | 2023-02-24 |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent VERU-111, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | Phase 3 | Terminated | Veru Inc. | 105 | 2021-06-24 | 2024-02-05 |
| Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension Pembrolizumab, Docetaxel, Prednisone - Prostatic Neoplasms | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 81 | 2020-09-23 | 2024-07-12 |
| Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography - Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8 | Phase 3 | Terminated | Jonsson Comprehensive Cancer Center | 54 | 2020-08-14 | 2023-01-17 |
| Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer Apalutamide, Enzalutamide - Prostate Cancer | Phase 3 | Terminated | Chinese University of Hong Kong | 74 | 2020-07-20 | 2026-10-27 |
| Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients Ferrotran® (Ferumoxtran-10) - Prostate Cancer, Metastasis | Phase 3 | Terminated | Saving Patients' Lives Medical B.V. | 172 | 2020-05-27 | 2026-04-28 |
| Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT Prednisone, Apalutamide, Abiraterone Acetate - Prostate Cancer | Phase 3 | Terminated | Dana-Farber Cancer Institute | 12 | 2020-04-20 | 2024-09-19 |
| Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer Radical prostatectomy (RP) followed by ePLND, Radical prostatectomy (RP) only - Prostate Cancer | Phase 3 | Terminated | Swiss Cancer Institute | 57 | 2019-08-27 | 2023-03-09 |
| Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) Pembrolizumab, Enzalutamide, Placebo - Prostatic Neoplasms | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1244 | 2019-07-28 | 2026-09-28 |
| Nutrition and Prostate Cancer Fermented Soy, Placebo - Prostate Cancer | Phase 3 | Terminated | Yale University | 19 | 2018-11-21 | 2021-05-26 |
| Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome Metformin, Placebo Oral Tablet - Prostate Cancer, Metabolic Syndrome | Phase 3 | Terminated | Canadian Urologic Oncology Group | 166 | 2018-07-12 | 2026-07-29 |
| Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer Degarelix, stereotactic body radiosurgery (SBRT) - Prostate Cancer | Phase 3 | Terminated | Memorial Sloan Kettering Cancer Center | 56 | 2017-03-28 | 2024-08-28 |
| A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease Degarelix, Leuprolide - Prostate Cancer | Phase 3 | Terminated | Ferring Pharmaceuticals | 545 | 2016-04-19 | 2022-06-29 |
| Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer. radiotherapy - Prostate Cancer | Phase 3 | Terminated | University Hospital, Ghent | 69 | 2016-04-01 | 2022-12-28 |
| A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC Galeterone, Enzalutamide - Prostate Cancer | Phase 3 | Terminated | LTN PHARMACEUTICALS, INC. | 953 | 2015-06-01 | 2023-03-15 |
| Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer Ciprofloxacin, Cefazolin - Prostate Cancer | Phase 3 | Terminated | CR-CSSS Champlain-Charles-Le Moyne | 158 | 2015-02-10 | 2025-02-12 |
| Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Denosumab (reduced dosing), Denosumab (standard dosing) - Metastatic Breast Cancer, Metastatic Prostate Cancer | Phase 3 | Terminated | Swiss Cancer Institute | 1380 | 2014-07-16 | 2026-10-23 |
| Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment. Prostatic arterial embolization using BeadBlock (Terumo) - Benign Prostatic Hyperplasia | Phase 3 | Terminated | University Hospital, Rouen | 2 | 2014-05-01 | 2015-07-30 |
Showing 20 of 70. Sign in to see all of them.
Prostatic Neoplasms (59) · Prostatic Hyperplasia (9) · Neoplasms (6) · Neoplasm Metastasis (5) · Lung Neoplasms (4) · Breast Neoplasms (3) · Erectile Dysfunction (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Prostatic Neoplasms, Castration-Resistant (2) · Agnosia (1) · Anemia (1) · Bone Neoplasms (1) · Brain Neoplasms (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1)
Genital Diseases (70) · Genital Diseases, Male (70) · Male Urogenital Diseases (70) · Urogenital Diseases (70) · Genital Neoplasms, Male (60) · Neoplasms by Site (60) · Urogenital Neoplasms (60) · Neoplasms (54) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (7) · Neoplastic Processes (5) · Signs and Symptoms (5) · Lung Diseases (4) · Respiratory Tract Diseases (4)
Docetaxel (9) · Leuprolide (9) · Prednisone (8) · Goserelin (7) · bicalutamide (7) · Radiotherapy (5) · Zoledronic Acid (4) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (4) · enzalutamide (4) · Flutamide (3) · Therapeutics (3) · Abiraterone Acetate (2) · Calcium Dobesilate (2) · Dexamethasone (2) · Doxorubicin (2)
Ferring Pharmaceuticals (3) · Ipsen (3) · M.D. Anderson Cancer Center (3) · Merck Sharp & Dohme LLC (3) · Sanofi (3) · Cell Genesys (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Northwestern University (2) · Swiss Cancer Institute (2) · Wake Forest University Health Sciences (2) · AEterna Zentaris (1) · Agennix (1) · AstraZeneca (1) · Auron Healthcare GmbH (1) · Bracco Diagnostics, Inc (1)
United States (37) · Canada (18) · Germany (17) · United Kingdom (13) · France (12) · Belgium (11) · Poland (10) · Czechia (8) · Italy (8) · Netherlands (8) · Spain (8) · Australia (6) · Hungary (6) · Austria (5) · Slovakia (5)
Andrew K. Lee, MD (1) · Anthony D'Amico, MD, PhD (1) · Arnoud Templeton, MD (1) · Ashok Hemal, MD (1) · Barrett Childs, MD (1) · Bernie Eigl, MD (1) · Bobak Djavan, Prof (1) · Carlos Santos, MD (1) · Carlos Vargas, MD (1) · Charles L. Bennett, MD, PhD (1)
PMID 34350976, PMID 15860850, PMID 16258090, PMID 22736604, PMID 23258223, PMID 23740935, PMID 24081940, PMID 24126237, PMID 24323035, PMID 24423462, PMID 26908063, PMID 31556911, PMID 32994091, PMID 33258687, PMID 33270906, PMID 33962579, PMID 34044584, PMID 34396210, PMID 34420143, PMID 34459214, PMID 35779938, PMID 38664019, PMID 38979716, PMID 40383193, PMID 40711960
P30CA016672 (2), 2005 (1), 2008 (1), 2014 (1), 2018 (1), P30CA012197 (1), U01DK060817 (1), U10CA045809 (1), U10CA081851 (1)